BiomEdit / News
Read the latest from BiomEdit
BiomEdit receives conditional licensure for first commercial product
BiomEdit's First-of-its-Kind Engineered Bacterial Biologic for Poultry Receives Conditional Licensure from USDA
Engineered biologic for poultry gets USDA conditional licensure
The Bird Bath: COE out of AVMA?, BiomEdit x Folium, UK Vets Narked
BiomEdit acquires Folium Science's microbiome technology and poultry feed additive
BiomEdit acquires Folium, readies 2 launches for Brazil
BiomEdit acquires England-based company's technology and pipeline assets
BiomEdit Acquires Folium Science Technology and Pipeline Assets to Expand Programmable Veterinary Biologics Capabilities
Advancing a First-of-Its-Kind Poultry Biologic with BiomEdit's Aaron Schacht
Eric Young Talks About BiomEdit's $18.4M Series B Deal of the Year Win
BiomEdit on the Move as First Product Nears Market
BiomEdit Wins 2026 Deal of the Year
BiomEdit Secures Foundational Patents for Engineered Probiotic Platform Positioned to Redefine Animal Health
Antibiotic Alternative Tackles Necrotic Enteritis in Broilers
BiomEdit Initiates Final Field Safety Trial for Non-Antibiotic Poultry Biologic, Advancing Toward USDA Conditional Licensure
IBJ Podcast: Here's How BiomEdit Raised $18.4M in a Tough VC Year
Are Big Shifts In Animal Health Coming? The Insiders + BiomEdit CEO Aaron Schacht Weigh In
BiomEdit Announces USDA Finding of No Significant Impact Letter for Non-Antibiotic Poultry Biologic, Clearing Path to Field Safety Trials
BiomEdit Necrotic Enteritis Treatment Clears USDA Hurdle
BiomEdit Partners with Bioversity International and Yale to Develop Rumen Digital Twin
Bezos Fund Supports Project to Develop Rumen AI Model
Greenfield-Based BiomEdit Receives $2 Million to Reduce Cattle Methane Emissions
BiomEdit Awarded Nearly $2 Million from Bezos Earth Fund to Advance AI Model for Methane-Reduction Strategies in Cattle
Engineered Bacteria Could Stop Poultry Necrotic Enteritis
BiomEdit Advances First-of-Its-Kind Engineered Bacteria Product to Final Development Phase, Secures Series B Funding and Adds Key Industry Leadership
BiomEdit Bets on Engineered Probiotic to Transform Animal Health and Productivity
Aaron Schacht on the Pharmaceutical Industry's Grand Challenge and Managing R&D at Scale
The Future of Food Biotechnology with Aaron Schacht of BiomEdit
Revisiting Animal Microbiome Health with BiomEdit's Aaron Schacht — Fresh Commentary
CEO Aaron Schacht Speaks at Ferment Conference
How It Works: Pipeline Project CPerf LLV* (BE-101)
BiomEdit Announces Advancement of a First-of-Its-Kind Engineered Bacteria Product into Full Pivotal Development to Combat Necrotic Enteritis in Broiler Chickens
BiomEdit's Aaron Schacht Named Visionary CEO in S&P Global Animal Health Awards
Researchers of New Scientific Review Paper Call for Additional Research to Fill Critical Gaps in Understanding Methane-Producing Microbes in Gut of Livestock
BiomEdit Awarded Grant to Develop Microbiome-Based Solution to Reduce Methane Emissions and Enhance Production Efficiency of Cattle in Africa and South Asia
Athian and BiomEdit Announce First-of-Its-Kind Collaboration to Develop Sustainability Protocols and Products in Parallel
Indiana Biosciences Research Institute and BiomEdit Announce Integrated Drug Discovery Collaboration
The IOS Of Synthetic Biology Is Here. And Thanks To This Incubator, The Apps Are Rolling In. (Forbes)
Nutreco Invests in BiomEdit, Strengthening Its Partnership to Transform Feed Additives Through Biome-actives
Microbiome Biotech Company BiomEdit Appoints Chairman and Board of Directors
Groundbreaking Collaboration Between Nutreco and BiomEdit Aims to Transform Feed Additives Through Microbiome Technology
PATHFINDER: A Conversation with Dr. Arvind Kumar, VP Research, BiomEdit
*Clostridium Perfringens Alpha Toxin and NetB Antibody Fragment, Live Limosilactobacillus Vector